Buy & Sell Nasdaq100 ETF (QQQ) – Nasdaq100 ETF Price Today
Aura AI Summary
Key Stats
- -Market Cap
- -Sector
- -7.45%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 58% Buy | 42% SellTrading Activity
- 151 daysTypical Hold Time
Over the past 52 weeks, Nasdaq100 ETF has traded between a low of $526.68 and a high of $746.16, highlighting its annual price range. Over the past three months, Nasdaq100 ETF has recorded a drawdown of -7.45%, reflecting recent price volatility. On average, investors hold Nasdaq100 ETF for approximately 151 days, indicating typical investor behavior on the platform.
About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Most Recent News
US government buys 10% stake in mining firms, signaling a new strategic investment trend.
In early 2026, the US government began acquiring stakes in American mining companies, including a 10% share in USA Rare Earth to support critical mineral projects. This move follows similar investments in Lithium Americas and Trilogy Metals, which sa...
FDA approves Sanofi's Tzield as first disease-modifying therapy for stage 3 type 1 diabetes in children.
The FDA has granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). This is the first disease-modifying therapy aimed at delaying the decline of insulin produc...
FDA approves Sanofi's Tzield as first disease-modifying therapy for newly diagnosed stage 3 type 1 diabetes in children.
The FDA granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). Tzield slows the decline of the body's insulin production by targeting the autoimmune process c...